Want to see NEO full AI Analyst Report?
NEO Stock Chart & Stats
$8.35
$0.52(2.83%)
At close: 4:00 PM EST
$8.35
$0.52(2.83%)
Day’s Range― - ―
52-Week Range$4.72 - $15.57
Previous CloseN/A
Volume108.49K
Average Volume (3M)1.87M
Market Cap
$1.85B
Enterprise Value$532.71M
Total Cash (Recent Filing)$146.14M
Total Debt (Recent Filing)$408.53M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Jul 28, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.83
Shares Outstanding130,211,780
10 Day Avg. Volume2,257,039
30 Day Avg. Volume1,867,457
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)0.36
Price to Sales (P/S)0.41
P/FCF Ratio-13.83
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue0.71
Enterprise Value/Gross Profit1.70
Enterprise Value/Ebitda-15.88
Forecast
1Y Price Target
$14.93Price Target Upside78.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)0.18
Revenue Forecast (FY)$800.44M
Bulls Say, Bears Say
Bulls Say
NGS Growth And Favorable Mix ShiftSustained NGS growth and a material mix shift toward higher‑complexity assays increase revenue per test and long‑run margin potential. As precision oncology adoption expands, NGS scale supports durable competitive advantage, stronger per‑unit economics, and diversification of clinical revenue.
Improving Cash Generation And LiquidityOperating cash flow turning positive and management guidance toward full‑year free cash flow positivity signal improved cash conversion. Durable improvement in cash generation reduces dependency on capital markets, supports reinvestment in sales and R&D, and strengthens ability to execute strategic initiatives over months.
Board Hire Enhances Data/AI Strategic CapabilityAdding a director with oncology real‑world data and AI leadership strengthens governance over data products and analytics strategy. This enhances the company's ability to monetize RWD, bolster pharma services, and embed AI into diagnostics—an enduring edge as oncology care shifts toward data‑driven decisioning.
Bears Say
Persistent Unprofitable OperationsDespite revenue growth, sustained negative net margins and a history of negative free cash flow indicate the cost base has not fully scaled to profitable operations. This structural profitability gap requires continued margin expansion or recurring external funding and limits durable shareholder value creation.
Payer And Reimbursement UncertaintyLong lead times for commercial payer coverage can delay revenue realization from new product launches and weigh on margins. Reimbursement uncertainty is a structural industry constraint that can materially slow scale and cash conversion of high‑value diagnostics over multiple quarters to years.
Nonclinical (pharma Services) WeaknessA decline in pharma and nonclinical services reduces revenue diversification and increases exposure to clinical volumes for growth. If pharma demand remains soft, it can amplify cyclicality, limit margin stability, and make overall revenue less resilient to healthcare macro trends.
NeoGenomics News
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $4.72 and its highest was $15.57 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $1.85B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Jul 28, 2026 which is in 17 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Apr 28, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of $0.006 by $0.004.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics pays a Notavailable dividend of $0.4 which represents an annual dividend yield of N/A. See more information on NeoGenomics dividends here
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.03.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 130,211,780 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0.01 in its last earnings report, beating expectations of $0.006. Following the earnings report the stock price went down -0.665%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in NEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeoGenomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.93 (78.79% Upside)
$14.93 (78.79% Upside)
Hedge Fund Trend
Decreased
By 522.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $118.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.74%
12-Months-Change
Fundamentals
Return on Equity
-11.82%
Trailing 12-Months
Asset Growth
-15.92%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
NEO Company Deck
NEO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial trajectory: consistent double-digit top-line growth, strong NGS performance (+26% YoY) with favorable mix shift (NGS now ~1/3 of clinical revenue), adjusted EBITDA expansion (+27% YoY), early commercial and reimbursement wins (PanTracer MolDX approval, RaDaR ST launch), and an increase to full-year revenue guidance. Offsetting risks include a meaningful nonclinical decline (-15% YoY), first-quarter gross margin headwinds (–80 bps) from acquisition and pre-approval launch timing, freight/fuel cost pressure, payer coverage timing for new products, and the need to refinance a sizable convertible in 2028. On balance, the positive growth, margin recovery plans, product launches, and improved cash flow prospects outweigh the near-term headwinds.View all NEO earnings summariesNEO Stock 12 Month Forecast
Average Price Target
$14.93
▲(78.79% Upside)
Technical Analysis
Ownership Overview
0.82% Insiders
26.52% Mutual Funds
0.16% Other Institutional Investors
38.57% Public Companies and
Individual Investors